fulvestrant has been researched along with Osteoporosis in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boue, SM; Bunnell, BA; Burow, ME; Elliott, S; Gimble, JM; Jiang, Q; Ohlstein, JF; Strong, AL; Wang, G; Zhang, Q; Zheng, S | 1 |
| Liu, M; Luo, Z; Rui, F; Sun, L | 1 |
| Komm, BS; Pickar, JH | 1 |
| Chen, WF; Lai, WP; Leung, PC; Mok, SK; Wang, XL; Wong, MS; Yao, XS | 1 |
| Choi, EM; Lee, YS | 1 |
| Kawamura, Y; Michihara, S; Moriyama, T; Tanaka, T; Uzawa, Y | 1 |
| Chow, HK; Lai, WP; Leung, PC; Mok, SK; Pang, WY; Wang, XL; Wong, KC; Wong, MS; Yao, XS | 1 |
| Gyokusen, M; Kaneko, S; Kondo, R; Sato, I; Sato, J; Sato, M; Shimizu, K; Tsutsui, M; Yamanaka, M | 1 |
| Evans, A; Healy, D; Vollenhoven, B | 1 |
2 review(s) available for fulvestrant and Osteoporosis
| Article | Year |
|---|---|
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2015 |
Modern antioestrogens and the coming revolution in women's health care.
Topics: Bone and Bones; Breast Neoplasms; Clomiphene; Estradiol; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Genital Diseases, Female; Humans; Isoflavones; Osteoporosis; Phytoestrogens; Plant Preparations; Plants; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 1999 |
7 other study(ies) available for fulvestrant and Osteoporosis
| Article | Year |
|---|---|
Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms.
Topics: Adult Stem Cells; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Drug Evaluation, Preclinical; Estradiol; Female; Fulvestrant; Humans; Inhibitory Concentration 50; Isoflavones; Mesenchymal Stem Cells; Osteogenesis; Osteoporosis; Phytoestrogens; Receptors, Estrogen | 2014 |
Icariin recovers the osteogenic differentiation and bone formation of bone marrow stromal cells from a rat model of estrogen deficiency-induced osteoporosis.
Topics: Animals; Bone Density Conservation Agents; Bone Marrow Cells; Cell Differentiation; Disease Models, Animal; Estradiol; Estrogen Receptor alpha; Female; Flavonoids; Fulvestrant; Mesenchymal Stem Cells; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Receptors, Progesterone; Up-Regulation | 2015 |
Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells.
Topics: Alkaline Phosphatase; Animals; Bone Density; Bone Density Conservation Agents; Cell Line; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Femur; Flavonoids; Fulvestrant; Gene Expression Regulation; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoporosis; Osteoprotegerin; Ovariectomy; Phosphorylation; RANK Ligand; Rats; RNA, Messenger; Tibia; Time Factors; Tomography, X-Ray Computed; Transfection | 2010 |
Costunolide stimulates the function of osteoblastic MC3T3-E1 cells.
Topics: Alkaline Phosphatase; Animals; Calcification, Physiologic; Cell Line; Collagen; Enzyme Inhibitors; Estradiol; Fulvestrant; KATP Channels; Mice; Nitric Oxide Synthase; Osteoblasts; Osteoporosis; Protein Kinases; Sesquiterpenes | 2011 |
Puerarin exerted anti-osteoporotic action independent of estrogen receptor-mediated pathway.
Topics: Acid Phosphatase; Amino Acids; Animals; Breast Neoplasms; Cell Proliferation; Diet; Estradiol; Female; Fulvestrant; Humans; Isoflavones; MCF-7 Cells; Mice; Osteocalcin; Osteoporosis; Ovariectomy; Pueraria; Receptors, Estrogen | 2012 |
Drynaria fortunei-derived total flavonoid fraction and isolated compounds exert oestrogen-like protective effects in bone.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Estradiol; Female; Femur; Flavanones; Flavonoids; Fulvestrant; Lumbar Vertebrae; Mice; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteoporosis; Osteoprotegerin; Ovariectomy; Phytoestrogens; Phytotherapy; Plant Extracts; Polypodiaceae; Rats; RNA, Messenger; Tibia | 2013 |
Estrogen-like activity and prevention effect of bone loss in calcium deficient ovariectomized rats by the extract of Pleurotus eryngii.
Topics: Animals; Bone Density; Bone Resorption; Calcium; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fulvestrant; Humans; Osteoporosis; Ovariectomy; Plant Extracts; Pleurotus; Rats; Rats, Sprague-Dawley | 2006 |